House Health Committee advances bill to expand childhood lead testing after debate over consent

The House Health Committee on Wednesday voted to report House Bill 9‑16 as amended, advancing a proposal to broaden blood lead testing for children and require insurance coverage for those tests. The committee approved the measure by a 15‑11 roll call after debate over parental consent rules.

Representative Jerral, the bill sponsor, told the committee that lead poisoning remains a sizable problem in Pennsylvania, saying an estimated 11,500 children are affected annually and that testing rates are low. “No child should suffer the lifelong harm from something that we have the tools to prevent,” Jerral said, arguing universal early testing would allow earlier detection and intervention.

The amended bill requires primary‑care providers to obtain two blood lead tests before a child’s second birthday and to ensure appropriate follow‑up testing (within 12 weeks) after a positive result; children not tested by age 2 would receive at least one test before age 6. The amendment, identified in committee as A03038, was described as aligning the statute’s expectations with current Medicaid practice and removes a cost‑sharing requirement.

Erica, who explained the bill to the panel, told members the legislation also requires distribution of educational materials from the Department of Health at hospitals, birth centers or via midwives for home births, and that pregnant patients should receive one blood lead test.

Representative Walsh opposed the bill’s original consent language, saying it would shift Pennsylvania from an informed‑consent framework to a presumption of testing with a conditional opt‑out. “Parents should be able to decline medical procedures without being required to document religious or philosophical reasoning,” Walsh said, adding that mandatory written objections could create confusion and pressure in clinical settings.

Committee members pressed for data during the discussion. Committee staff and an executive director identified 2022 figures cited in the hearing: roughly 182,790 blood lead tests were performed and 7,332 children under age 6 had elevated blood lead levels in that year; the transcript records an exchange where the precise units for the threshold (reported as 3.5) were questioned.

Several providers voiced support for the change. Representative Connors, speaking from a provider perspective, said the bill aligns with CDC and American Academy of Pediatrics guidance and stressed the clinical urgency: “I can tell you as a provider, the terror of having a lead test come back on one of these kids positive,” Connors said, urging that tests be covered without cost sharing so families are not deterred.

Chair Frankel noted the committee adopted the amendment and clarified to members that the amendment eliminates the cost‑sharing provision. After debate and the roll call, the committee reported HB 9‑16 as amended.

The committee did not take any additional procedural steps on implementation dates or detailed reporting requirements during the meeting. With no further business, Chair Frankel adjourned the committee meeting.